Press coverage about Athersys (NASDAQ:ATHX) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Athersys earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.8774676587959 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Is The Stock Risky? (Beta Analysis) – Athersys Inc (NASDAQ: ATHX) – Stocks Pen (stockspen.com)
- Athersys, Inc. (ATHX) : Keep an eye on Analysts Rating – Wall Street Morning (wallstreetmorning.com)
- Hot Stock under Consideration – Athersys Inc (NASDAQ: ATHX) – Alpha Beta Stock (alphabetastock.com)
- Hot Stock under Consideration – Athersys Inc (NASDAQ: ATHX) – Stocks Pen (stockspen.com)
- Athersys: Is It Worth Your Time? – Seeking Alpha (seekingalpha.com)
A number of research firms have commented on ATHX. ValuEngine upgraded shares of Athersys from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Maxim Group set a $12.00 price objective on shares of Athersys and gave the company a “buy” rating in a research note on Thursday, November 16th.
In other Athersys news, COO William Lehmann, Jr. sold 14,000 shares of the stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $1.80, for a total transaction of $25,200.00. Following the transaction, the chief operating officer now directly owns 503,712 shares in the company, valued at approximately $906,681.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 29,000 shares of company stock worth $51,075 over the last quarter. 9.40% of the stock is currently owned by insiders.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.